P1101, phase 1, healthy volunteers
Showing 26 - 50 of >10,000
Type 2 Diabetes Trial in Daejeon (CT-L01 12.5/1,000 mg)
Completed
- Healthy
- CT-L01 12.5/1,000 mg
-
Daejeon, Korea, Republic ofChungnam National University Hospital
Jan 10, 2023
Non-alcoholic Steatohepatitis Trial (INI-822 (A), Placebo (B))
Not yet recruiting
- Non-alcoholic Steatohepatitis
- INI-822 (A)
- Placebo (B)
- (no location specified)
Jul 6, 2023
Healthy Trial in Toronto (ABX1100 injection for IV infusion, Placebo injection for IV infusion)
Recruiting
- Healthy
- ABX1100 injection for IV infusion
- Placebo injection for IV infusion
-
Toronto, CanadaStudy Site
Oct 25, 2023
Type 2 Diabetes Trial in Daejeon (CT-L01, Alogliptin Benzoate 25 mg, Metformin HCl XR 1,000 mg)
Completed
- Healthy
- CT-L01
- +2 more
-
Daejeon, Korea, Republic ofChungnam National University Hospital
Jan 10, 2023
Healthy Volunteers Trial in Saint Paul (Recombinant human plasma gelsolin, )
Recruiting
- Healthy Volunteers
- Recombinant human plasma gelsolin
- placebo
-
Saint Paul, MinnesotaNucleus Network
Mar 16, 2023
Infections, Vector Borne Diseases, Systemic Inflammatory Response Syndrome Trial in Brisbane (MMV367, P. falciparum IBSM
Recruiting
- Infections
- +11 more
- MMV367
- P. falciparum IBSM infection
-
Brisbane, Queensland, Australia
- +1 more
Jul 30, 2023
Immune System Diseases, Autoimmunity Trial in Hialeah (HIB210, Placebo)
Recruiting
- Immune System Diseases
- Autoimmunity
- HIB210
- Placebo
-
Hialeah, FloridaHI-Bio Investigational Site
Jul 6, 2023
Intrahepatic Cholangiocarcinoma Trial in Shanghai (HMPL-453, Rabeprazole)
Active, not recruiting
- Intrahepatic Cholangiocarcinoma
-
Shanghai, Shanghai, ChinaShanghai Xuhui Central Hospital
Jun 24, 2023
Bladder Cancer Trial in Melbourne (APL-1202 and APL-1501 (Single ascending dose), APL-1202 and APL-1501 (Multiple Ascending
Not yet recruiting
- Bladder Cancer
- APL-1202 and APL-1501 (Single ascending dose)
- APL-1202 and APL-1501 (Multiple Ascending dose)
-
Melbourne, Victoria, AustraliaNucleus Network Pty Ltd
Sep 11, 2023
Pharmacokinetics Trial in Oslo (GE200486 0.5M Injection)
Completed
- Pharmacokinetics
- GE200486 0.5M Injection
-
Oslo, NorwayRikshospitalet
Dec 29, 2022
Hypertension Trial in Seoul (BR1015, BR1015-1, BR1015-2)
Not yet recruiting
- Hypertension
- BR1015
- +2 more
-
Seoul, Gwanakgu, Korea, Republic ofClinical Research Center, H PLUS Yangji Hospital
Aug 16, 2023
Hypertension Trial in Seoul (BR1015, BR1015-1, BR1015-2)
Active, not recruiting
- Hypertension
- BR1015
- +2 more
-
Seoul, Gwanakgu, Korea, Republic ofClinical Research Center, H PLUS Yangji Hospital
Aug 22, 2023
Healthy Volunteer Trial in Montreal (RLS-0071, Saline Placebo)
Completed
- Healthy Volunteer
- RLS-0071
- Saline Placebo
-
Montreal, Quebec, CanadaAltasciences
Mar 25, 2022
Healthy Subjects Trial in Christchurch (EC5026 oral tablet, Placebo oral tablet)
Not yet recruiting
- Healthy Subjects
- EC5026 oral tablet
- Placebo oral tablet
-
Christchurch, New ZealandNew Zealand Clinical Research
Oct 17, 2023
Multiple Sclerosis Trial in London (PIPE-307)
Completed
- Multiple Sclerosis
-
London, United KingdomHammersmith Medicines Research
Oct 4, 2022
Alzheimer's Disease Trial (CS6253 Solution for Injection, Placebo)
Not yet recruiting
- Alzheimer's Disease
- CS6253 Solution for Injection
- Placebo
- (no location specified)
Jul 20, 2023
Healthy Volunteers Trial in Melbourne (Verasone)
Not yet recruiting
- Healthy Volunteers
-
Melbourne, Victoria, AustraliaNucleus Network
Nov 19, 2023
Hereditary Angioedema Trial in Adelaide (ADX-324, Placebo)
Recruiting
- Hereditary Angioedema
- ADX-324
- Placebo
-
Adelaide, South Australia, AustraliaCMAX Clinical Research
Jan 10, 2023
Drug Interaction Trial in Uppsala (Drug Drug Interaction)
Recruiting
- Drug Interaction
- Drug Drug Interaction
-
Uppsala, SwedenCTC Clinical Trial Consultants AB
Apr 13, 2023
Overweight or Obesity Trial in Uppsala (Xenical® vs EMP 22, EMP 22 vs Xenical®, EMP 16 vs Xenical®)
Not yet recruiting
- Overweight or Obesity
- Xenical® vs EMP 22
- +2 more
-
Uppsala, SwedenCTC Clinical Trial Consultanta AB
Aug 25, 2023